Repligen (NASDAQ:RGEN) Shares Gap Up – Still a Buy?

Repligen Co. (NASDAQ:RGEN) shares gapped up prior to trading on Tuesday . The stock had previously closed at $131.64, but opened at $138.51. Repligen shares last traded at $137.52, with a volume of 137,521 shares trading hands.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. StockNews.com downgraded shares of Repligen from a “hold” rating to a “sell” rating in a report on Thursday, April 17th. Canaccord Genuity Group dropped their price target on shares of Repligen from $170.00 to $150.00 and set a “hold” rating on the stock in a research note on Wednesday, April 16th. TD Cowen started coverage on Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price objective for the company. Evercore ISI started coverage on Repligen in a research report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 target price for the company. Finally, JPMorgan Chase & Co. increased their price target on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $176.82.

Repligen Stock Performance

The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The stock has a fifty day moving average of $140.09 and a 200-day moving average of $145.74. The firm has a market capitalization of $7.83 billion, a P/E ratio of -274.53, a P/E/G ratio of 4.54 and a beta of 1.27.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. On average, research analysts anticipate that Repligen Co. will post 1.72 EPS for the current year.

Insider Buying and Selling at Repligen

In related news, Director Margaret Pax purchased 250 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. The trade was a 31.53 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

Several large investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD increased its stake in Repligen by 11.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock worth $1,027,165,000 after acquiring an additional 743,815 shares during the last quarter. Point72 Asset Management L.P. raised its position in Repligen by 183.1% during the fourth quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company’s stock valued at $132,227,000 after acquiring an additional 594,189 shares in the last quarter. Groupama Asset Managment increased its holdings in Repligen by 12,321.0% in the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company’s stock worth $58,142,000 after acquiring an additional 400,680 shares in the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Repligen during the 4th quarter worth approximately $53,428,000. Finally, Raymond James Financial Inc. purchased a new position in Repligen during the fourth quarter worth about $52,492,000. 97.64% of the stock is currently owned by institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.